Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| basal cell | 15 studies | 37% ± 18% | |
| epithelial cell | 7 studies | 36% ± 16% | |
| keratinocyte | 5 studies | 57% ± 29% | |
| ciliated cell | 3 studies | 34% ± 14% | |
| secretory cell | 3 studies | 42% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 39% | 7273.06 | 557 / 1445 | 88% | 261.55 | 161 / 183 |
| ureter | 0% | 0 | 0 / 0 | 100% | 32.23 | 1 / 1 |
| tonsil | 0% | 0 | 0 / 0 | 98% | 234.38 | 44 / 45 |
| bladder | 29% | 1007.67 | 6 / 21 | 68% | 98.66 | 341 / 504 |
| skin | 72% | 21536.22 | 1303 / 1809 | 9% | 8.94 | 42 / 472 |
| pancreas | 0% | 0 | 0 / 328 | 74% | 60.66 | 131 / 178 |
| intestine | 4% | 80.54 | 41 / 966 | 68% | 71.28 | 356 / 527 |
| uterus | 1% | 180.17 | 2 / 170 | 66% | 192.68 | 305 / 459 |
| stomach | 1% | 16.33 | 2 / 359 | 59% | 65.36 | 168 / 286 |
| lung | 0% | 3.12 | 1 / 578 | 56% | 101.23 | 652 / 1155 |
| breast | 22% | 477.41 | 99 / 459 | 25% | 25.50 | 281 / 1118 |
| prostate | 11% | 262.75 | 26 / 245 | 6% | 3.08 | 29 / 502 |
| thymus | 0% | 0 | 0 / 653 | 11% | 7.32 | 67 / 605 |
| adipose | 1% | 46.75 | 15 / 1204 | 0% | 0 | 0 / 0 |
| ovary | 0% | 0 | 0 / 180 | 1% | 0.39 | 5 / 430 |
| kidney | 0% | 0 | 0 / 89 | 1% | 0.49 | 5 / 901 |
| liver | 0% | 0 | 0 / 226 | 0% | 0.26 | 2 / 406 |
| adrenal gland | 0% | 0 | 0 / 258 | 0% | 0.11 | 1 / 230 |
| muscle | 0% | 5.71 | 1 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 1.67 | 1 / 929 | 0% | 0 | 0 / 0 |
| blood vessel | 0% | 12.87 | 1 / 1335 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| brain | 0% | 0 | 0 / 2642 | 0% | 0 | 0 / 705 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| heart | 0% | 0 | 0 / 861 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
| GO_0030198 | Biological process | extracellular matrix organization |
| GO_0050678 | Biological process | regulation of epithelial cell proliferation |
| GO_0002009 | Biological process | morphogenesis of an epithelium |
| GO_0060512 | Biological process | prostate gland morphogenesis |
| GO_0010951 | Biological process | negative regulation of endopeptidase activity |
| GO_0001533 | Cellular component | cornified envelope |
| GO_0005615 | Cellular component | extracellular space |
| GO_0016528 | Cellular component | sarcoplasm |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | SERPINB5 |
| Protein name | Serpin B5 (Maspin) (Peptidase inhibitor 5) (PI-5) Serpin family B member 5 |
| Synonyms | PI5 |
| Description | FUNCTION: Tumor suppressor. It blocks the growth, invasion, and metastatic properties of mammary tumors. As it does not undergo the S (stressed) to R (relaxed) conformational transition characteristic of active serpins, it exhibits no serine protease inhibitory activity. |
| Accessions | P36952 ENST00000489441.5 [P36952-2] ENST00000424602.1 C9JLM5 ENST00000382771.9 [P36952-1] |
